TABLE 2.
Group | No. of dogs positive/total no. of dogs (%)
|
||
---|---|---|---|
GBL | BCS | BMS | |
Dogs with active lesions | 2/11 (18.18) | 2/11 (18.18) | |
Dogs with scars | 2/11 (18.18) | 2/11 (18.18) | |
Dogs without lesions or scars | 27/380 (7.11) | 16/201 (7.96) | 8/46 (17.39) |
Dogs from which BMS were taken | 5/46 (10.87) | 6/46 (13.04) | 8/46 (17.39) |
Dogs from which BMS were not taken | 4/34 (11.76) | 5/34 (14.71) | |
Dogs from which BMS were not taken and BCSs were not tested | 22/322 (6.83) | ||
Dogs from which BMS were not taken and GBLs were not tested | 9/143 (6.29) |
NOTE Field samples were amplified with the B1-B2 primer pair and the products were then hybridized with γ-32P-labelled B3 probe as described in Materials and Methods.